Objectives: The iron-oxide nano-particles were used in experimental setting for MR-angiography for many years. The aim of this work is to assess the image quality, vessel visibility and safety of ferumoxtran-enhanced MR-angiography of the pelvic area in prospective setting. Methods: In this prospective trial ferumoxtran-enhanced MR-angiography was performed 24-36 hours after ferumoxtran infusion using T1w sequences of the pelvis. Three radiologists read the images. A five-point scala for assessment of image quality and vessel visibility was used (very poor, poor, moderate, good and excellent). Additionally, safety data were acquired (Treatment-Emergent Adverse Events = TEAEs). Results: 160 patients were included in the study. Three readers evaluated and rated the ferumoxtran-enhanced MR-angiography in terms of vessel visibility as good or excellent in 85.5% and image quality as good and excellent in 76.5%. In three cases (1.9%) the vessel visibility and image quality were rated very poor. However, two of these three patients were underdosed due to a handling failure. Regarding safety, ferumoxtran was found to be well-tolerated and safe. Nine patients experienced mild/moderate adverse events (5,6%). Only one patient (0.6%) experienced serious TEAE. Conclusion: Ferumoxtran-enhanced pelvic MR-angiography showed very promising image quality and vessel visibility in our patient group. Reading the safety, it was found to be well-tolerated and safe.